<DOC>
	<DOCNO>NCT00148499</DOCNO>
	<brief_summary>The purpose trial investigate efficacy tolerability lozenges contain 20 mg mbroxol hydrochloride ( Mucoangin ? ) relative lozenge contain placebo lozenge contain 3 mg benzocaine relieve pain sore throat patient suffer acute viral pharyngitis .</brief_summary>
	<brief_title>Efficacy Tolerability Ambroxol Lozenge 20 mf Relieving Pain Sore Throat Pat . With Acute/Viralpharyngitis</brief_title>
	<detailed_description>This randomise , double-blind , placebo- active-controlled parallel group study adult pat ients , suffer acute viral pharyngitis throat pain least moderate intensity . The whole study last 4 day , test day patient take one lozenge cont aining Ambroxol hydrochlorid 20 mg/ placebo/ benzocaine lozenge 3 mg 6 lozenge per day . Using Patient Diaries assessment tolerability efficacy patient obtain . Study Hypothesis : The primary hypothesis test test superiority ambroxol 20 mg comparison placebo . If corresponding test superiority placebo statistically significant , hypothesis non-inferiority broxol 20 mg comparison benzocaine 3 mg test . Comparison ( ) : For primary comparison placebo lozenge use , secondary comparison benzocaine 3 mg lozenge use .</detailed_description>
	<mesh_term>Pharyngitis</mesh_term>
	<mesh_term>Benzocaine</mesh_term>
	<mesh_term>Ambroxol</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Patients sore throat acute viral pharyngitis . 2 . Female male patient age 18 80 year . 3 . The throat pain intensity rat least moderate VRS ( PI ) . 4 . Written Informed Consent give patient . 5 . Compliance patient seem guarantee , patient seem able understand complete patient diary . 6 . Patient able remain doctor 's practice initial 3 hour follo wing first intake study medication , able return study visi t . EXCLUSION CRITERIA 1 . Female patient childbearing potential : 1 . Pregnant 2 . Currently breastfeed 3 . NOT practice acceptable method birth control , NOT plan contin ue practice acceptable method throughout study . Acceptable method birth control include surgical sterilisation , intra uterine device , oral , implan table , injectable contraceptive doublebarrier method . 2 . Patients symptoms primarily bacterial pharyngitis bacterial secon dary infection ( clinical finding inter alia assessment exudate ) . 3 . First indication symptom acute pharyngitis ( e.g . sore throat ) occurre 3 day ago . 4 . Patients suffer acute viral bacterial pharyngitis past 4 week . 5 . Patient past week , study require treatment following : antibiotic steroid oral , inhale topical application expectorant antitussives . No physical therapy ( e.g . throat compress , throa rinse ) may apply trial . Patients use analgesic antiinflammatory agent less two halflives applicable drug study entry , require use 3 hour take firs lozenge . 6 . Patients mouth breathe result nasal congestion . 7 . Known hypersensitivity Ambroxol auxiliary substance contain lozenge . 8 . Existing tumour condition currently treatment . 9 . Alcohol , and/or drug abuse . 10 . Any clinical condition , opinion investigator would llow safe completion protocol safe administration trial medication . 11 . Any investigational therapy within 30 day prior randomisation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>